Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24043129 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Frederik Fabian Feigl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Fraunhofer Institute for Cell Therapy and Immunology (IZI), 04103 Leipzig, Germany. Hauptthemen laut MEDLINE: Neoplasms, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fraunhofer Society, Fraunhofer Internal Program.
Abstract (Originalsprache)
Natural killer (NK) cells are a subset of lymphocytes that offer great potential for cancer immunotherapy due to their natural anti-tumor activity and the possibility to safely transplant cells from healthy donors to patients in a clinical setting. However, the efficacy of cell-based immunotherapies using both T and NK cells is often limited by a poor infiltration of immune cells into solid tumors. Importantly, regulatory immune cell subsets are frequently recruited to tumor sites. In this study, we overexpressed two chemokine receptors, CCR4 and CCR2B, that are naturally found on T regulatory cells and tumor-resident monocytes, respectively, on NK cells. Using the NK cell line NK-92 as well as primary NK cells from peripheral blood, we show that genetically engineered NK cells can be efficiently redirected using chemokine receptors from different immune cell lineages and migrate towards chemokines such as CCL22 or CCL2, without impairing the natural effector functions. This approach has the potential to enhance the therapeutic effect of immunotherapies in solid tumors by directing genetically engineered donor NK cells to tumor sites. As a future therapeutic option, the natural anti-tumor activity of NK cells at the tumor sites can be increased by co-expression of chemokine receptors with chimeric antigen receptors (CAR) or T cell receptors (TCR) on NK cells can be performed in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fraunhofer Institute for Cell Therapy and Immunology (IZI), 04103 Leipzig, Germany.
- Chair of Tissue Engineering and Regenerative Medicine (TERM), University Hospital of Würzburg, 97070 Würzburg, Germany.
- Translational Center Regenerative Therapies, Fraunhofer Institute for Silicate Research (ISC), 97070 Würzburg, Germany.
- Institute for Clinical Immunology, University of Leipzig, 04103 Leipzig, Germany.
Förderung
- Fraunhofer Society
- Fraunhofer Internal Program
Zitieren
APA
Feigl, F. F., Stahringer, A., Peindl, M., Dandekar, G., Koehl, U., Fricke, S., & Schmiedel, D. (2023). Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043129
Vancouver
Feigl FF, Stahringer A, Peindl M, Dandekar G, Koehl U, Fricke S, et al. Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043129
BibTeX
@article{Feigl2023,
author = {Feigl, Frederik Fabian and Stahringer, Anika and Peindl, Matthias and Dandekar, Gudrun and Koehl, Ulrike and Fricke, Stephan and Schmiedel, Dominik},
title = {Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24043129}
}
EUVIMED